Abstract
A study published in JAMA Psychiatry found that there is a need to look at the association with autism spectrum disorder (ASD) and prenatal exposure to medications that affect neurotransmitters. That study, published in December 2018 and written by Magdalena Janecka, Ph.D., and colleagues, found that children exposed in utero to cannabinoid receptor agonists, muscarinic receptor 2 agonists, opioid receptor κ and ε agonists, or α2C‐adrenergic receptor agonists had no increased risk of ASD. Children exposed prenatally to antagonists of neuronal nicotinic acetylcholine receptor α had higher risks of ASD. However, replication and/or validation was recommended.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
